=========================================================================== Asthma Therapies 2004 - Clinical Trials, Novel Treatments and Drug Delivery 15th and 16th December 2004 - Workshop: 14th December 2004 Hilton Kensington Hotel, London =========================================================================== **** CONFERENCE BROCHURE AVAILABLE - REQUEST YOURS NOW ****
THEMES WILL INCLUDE: **Learn from the experts: Altana presents on new inhaled corticosteroid, Ciclesonide **New information on innovative Drug Roflumilast **Identify Key Market Trends and Profit from **Emerging Developments in Asthma Therapeutics **Future Targets in Asthma Therapeutics - Genetic and Genomic Approaches; JNK; Chemokine Receptor Antagonists **Learn how to get your Pipeline drugs to the Market Faster **How Pharma Companies can make Successful and Lucrative Alliances with Drug Delivery Companies **Learn from leading manufacturers, including 3M and Bespak
KEY SPEAKERS **Dr. Dirk Bredenbroeker, Head, Clinical Research Pulmonology, Altana **Dr. Noel Snell, Global Clinical, Respiratory Medicine, AstraZeneca **Dr. James Stefely, Senior Research Specialist, 3M **Dr. Anthony Coyle, Director, Millennium **Dr. Kate Blease, Senior Scientist, Celgene **Dr. Frank Cerasoli, Director of Medical Relations, Altana **Dr. John Pritchard, Manager, Inhalation Therapy, 3M **Doug Smalley, Director, Business Development, Vectura **Dr. Tol Purewal, Head of Research and Development, Bespak Europe Ltd **Dr. Troels Keldman, Managing Director, Direct Haler **Richard Turner, Sales Manager, Pharmaceutical Division, Presspart Manufacturing **Dr Alan Jones, Director & Academic General Practitioner, Clintrials Wales
----------------------------------------------------------------- This event will also feature: Pre-conference Interactive Workshop -----------------------------------------------------------------
+Forcasting the Commercial Potential for Respiratory Products+ Led by: Gary Johnson, Managing Director, Inpharmation
+Working Together to Produce the Next Generation of Asthma Products+ Led by: Phil Seeney, Product and Process Engineering, PA Consultancy
WHO SHOULD ATTEND THIS EVENT: **Director Respiratory Disease **Global Clinical Expert Respiratory Medicine **Senior Distinguished Scientist, Respiratory **Vice President, Research **Director, Worldwide Epidemiology **Executive Director, Respiratory and Allergy **Head of Clinical Research, Pulmonology **Vice President, Respiratory Clinical Medicine and Medical Affairs **Global Director, Respiratory Science **Associate Director, Product Development **Head, Asthma Research **Head, Pharmacology **President, Signal Research Development **Executive Vice President Research and Development **Pharmaceutical Operations Director **Executive Vice President, Research
--------------------- DELEGATE REGISTRATION ---------------------
Places at this event are strictly limited so BOOK YOUR PLACE NOW. To make a booking on this event, please contact me via phone or email. Book early to secure a place.
- PRICING -
Attend the: 2 Day conference with interactive workshop - ONLY GBP1600 plus VAT 2 Day conference - ONLY GBP1299 plus VAT Workshop only - ONLY GBP650 plus VAT
- BOOKINGS -
Booking is easy, simply contact me on:
Telephone: +44 (0)20 8767 6711 Fax: +44 (0)20 8767 5001 Terms and conditions apply - see below Email: mailto:andrew.oliver@visongaingroup.com
Please find below the conference agenda. To book your place at simply give me a quick ring or email me stating whether you require a single place or a group booking. I look forward to hearing from you soon.
**** FULL CONFERENCE AGENDA BELOW ****
================================================== PRE-CONFERENCE WORKSHOP Tuesday 14th December 2004 ================================================== Morning Session: Forcasting the Commercial Potential for Respiratory Drugs * Discover the pitfalls of patient based forcasting and learn how to make accurate forcasts * Pricing: What allows premium pricing for respiratory products and how to guage how big the premium can be. * How the 'big three' factors in market share function for respiratory products * Devices: to what extent do the NCE or the device drive commercial success? Led by: Gary Johnson, Managing Director, Inpharmation
Afternoon Session: Working Together to Produce the Next Generation of Asthma Products * Reacting to turbulent and changing product lifecycles * Explore the opportunity to rethink traditional development methods * Investigate how the product development model will change in the future * Learn how your company can influence the product development approaches of the future Led by: Phil Seeney, Product and Process Engineering, PA Consulting
Schedule: The workshops will run from 10:00 until 16:30 with lunch and refreshments at appropriate intervals
============================= DAY 1 Wednesday 15th December =============================
09:00 Registration and coffee
09:30 Opening remarks from the Chair John Pritchard, Manager Inhalation Therapy, 3M
NEW DRUGS IN THE ASTHMA PIPELINE
09:40 OPENING KEYNOTE SPEAKER
Roflumilast - PDE IV inhibitors for asthma and COPD * How to target PDEIV Inhibitors to develop innovative asthma therapies * Update and results of phase III clinical trials * Role of PDE IV inhibitors in modulating inflammatory cells -how effective are they? * How to reduce the side effects Dr Dirk Bredenbroeker, Head, Clinical Research Pulmonology Altana
FUTURE TARGETS FOR ASTHMA THERAPIES
10:20 The Development of Effective Strategies for Asthma Management and Future Impact of New Treatments * How physicians and patients have responded to growing morbidity and risk * Asthma Treatment Guidelines - why aren't they observed? * The impact of new treatments - fixed combinations - contribution of leukotrienes * Concomitant diseases and their implications for asthma treatment * The future of the Asthma Market Graham Lewis, Vice President, Europe Pharma Strategy IMS Health
11:00 Morning Coffee
11:20 JNK - Controlling Multiple Inflammatory Cytokines: Focus and SP600125 * Mediators and mechanisms of JNK inhibitors involved in asthma * Hyperresponsiveness, lung inflammation and airways remodelling - how JNK inhibitors affect animal models * JNK inhibitors or corticosteroids - which is most beneficial to you? * CASE STUDY: SP600125 Celgene - results from recent studies Dr. Kate Blease, Senior Scientist Celgene
12:00 Antiinflammatory Therapies - Chemokine Receptor Antagonists: Exploring Future Possibilities * Chemokines as mediators of inflammation - regulation and attraction of leukocytes to the inflammed area * How chemokines interact with their receptors - CCR3 and the Eotaxins * Blockade of CCR3 function by small molecules * Future directions for anti-CCR3/Eotaxin therapies - what is the potential for your company? Dr. James Pease, Senior Lecturer Imperial College
12:40 LUNCH
CLINICAL TRIALS IN ASTHMA
14:00 How to Select Appropriate Clinical Endpoints in Asthma Studies * Regulatory requirements for asthma studies - how they affect your trials * Secondary endpoints, surrogate endpoints and proof of principle in asthma trials * Examples of clinical endpoints - how they can be adapted for your trials * Potential endpoints for disease-modifying agents * Safety Assessments - where you can refine policies Dr. Noel Snell, Global Clinical Expert, Respiratory Medicine AstraZeneca
14.40 Challenges in Asthma Research at the Primary Care/ Patient Interface * Patients perception of Asthma - distancers, deniens & progmatists. * The New General Practice Contract - help or hindrance in asthma research. * Anti Inflammatory studies - challenges and opportunities * The appropriateness of clinical end points. * General practice networks - strengths & weaknesses. Dr Alan Jones, Director, & Academic General Practitioner Clintrials Wales
15:20 Afternoon Tea
15:40 How to Treat Co-existing Allergic Rhinitis and Allergic Asthma * How to reduce the severity of allergic asthma symptoms by treatment of co-existing allergic rhinitis * New ARIA and IPAG guidelines - calls for integrated therapy in the treatment of allergic rhinitis and asthma * Initiative from drug delivery - medication systems for integrated therapy * The second-generation multiple-route respiratory combination therapy concept Dr. Troels Keldman, Managing Director Direct Haler
16.20 Questions and Discussion
16.30 Summation of day one from conference chair
16.40 Close of Day One
============================ DAY 2 Thursday 16th December ============================
09:00 Registration and Coffee
09:30 Opening remarks from the Chair, John Pritchard, Manager Inhalation Therapy, 3M
NEW DRUGS IN THE ASTHMA PIPELINE
09:40 OPENING KEYNOTE SPEAKER
CASE STUDY: Ciclesonide - Safety Profile of New Inhaled Corticosteroids * What to expect from an ideal inhaled corticosteroid * Phase III clinical studies - how to ensure safety and efficacy * Topical and systematic safety - new methods of eliminating side effects * HPA axis function - results from pharmacodynamic studies Dr Frank Cerasoli, Director of Medical Relations Altana
10:20 Genetic and Genomic Approaches to Understanding Asthma * How to identify human genes as future targets for asthma therapy- the impact of genetics on asthma therapy * Murine experimental genetic model - how they help in human asthma * Speed up your identification of genetic loci - genetic and genomic technologies * How to regulate innate and adaptive immune system interface * Asthma Genetics and the Genetics of other inflammatory diseases Dr. Andrea Heinzmann University of Freiburg
11:00 Morning Coffee
11:20 New Developments in Asthma Therapy - Ventures for your Company * Targets in asthma research - past present and future * Areas for growth: where can your company enter the asthma market? * Outlook: new targets for pain relief ligands and the future for pain therapies in the clinic * CFCs to HFAs: advice on how best to make the transition to comply with new guidelines * What are the new combination drugs dominating the market? * Regulation changes - how will they affect your pipeline? Dr. Anthony Coyle, Director Millennium
THE INCREASING IMPORTANCE OF DRUG DELIVERY SYSTEMS
12:00 Drug Delivery and Pharma Companies - Learn from the best: Vectura and Skyepharma * How a successful partnership can benefit your company * How to select a device development for asthma medication * Technical influences on the choice of delivery device for asthma therapies Doug Smalley, Director of Business Development Vectura Group Plc
12:40 Lunch
14:00 pMDI: The Transition from "Safe, Compatible & Stable Containment" to "Complex and Integral Drug Delivery Device Component" * The Evolution, once a safe and stable environment, and now! * Critical Success Factors - precise and robust * Performance demands, recent innovations for pMDIs - new molecules and therapeutic opportunities * Regulatory requirements - raising the bar * The Way Ahead - Challenges, Solutions & Opportunities Richard Turner, Sales Manager, Pharmaceutical Division Presspart Manufacturing
14:40 Accelerating the Development of Inhaled Drugs * Obtaining the best balance - how to eliminate unsuccessful compunds and minimise development time * How to chose the best delivery system in early trials * Which is the best approach? - DPIs, MDIs or Nebulisers * How to meet the regulatory challenges John Pritchard, Manager of Inhalation Therapy 3M
15:20 Afternoon Tea
15:40 CASE STUDY: Bespak: The MDI Valve Evolution * Short historical perspective - lessons to be learned from the past * Current valves and their performance - how your drugs can benefit * Innovative improvements in design - Chamberless valves and no-prime valves * Future developments: next generation metered valves with improved dose consistency Dr Tol Purewal, Head of Research and Development Bespak Europe Ltd
16:20 CASE STUDY: Future Benefits from New formulation approaches: Particle Engineering and New Excipients * 3M's development of HFA-compatible excipients : Suspension,solutions and sustained release delivery * How to improve delivery to the lungs - particle engineering of drugs and excipients * HFA propellant system compatibility with protein and peptide formulations Dr James Stefely, Senior Research Specialist 3M
17:00 Questions and Discussion
17:20 Chairman summation
17:30 Close of Conference
Terms & Conditions NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below. Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.
Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.
To unsubscribe please reply with unsubscribe in the subject line.
Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. If you wish your details to be amended, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively please reply with unsubscribe in the subject line. Please allow approximately 7 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.
************************************************************** Scanned by VisNetic MailScan for SMTP Servers. Visit http://www.deerfield.com/products/visnetic_mailscan. **************************************************************